Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations

Documenti analoghi

• Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial
  di: Paula Cramer, et al.
  Pubblicazione: (2024)
• Chronic lymphocytic leukemia with IGH :: BCL3 ‐translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape
  di: Cosima Drewes, et al.
  Pubblicazione: (2026)
• Transition Into Clinical Routine and Survival Outcomes of BCL2 ‐ and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry
  di: Nadine Kutsch, et al.
  Pubblicazione: (2026)
• Hybrid immunity to SARS‐CoV ‐2 in patients with chronic lymphocytic leukemia
  di: Sibylle C. Mellinghoff, et al.
  Pubblicazione: (2024)
• Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities
  di: Kostas Stamatopoulos, et al.
  Pubblicazione: (2024)